Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Similar Items

• Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
  by: Zarir F. Udwadia, et al.
  Published: (2021-02-01)
• Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
  by: Mahender Kumar Medisetty, et al.
  Published: (2021-04-01)
• Role of favipiravir in the treatment of COVID-19
  by: Shashank Joshi, et al.
  Published: (2021-01-01)
• Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
  by: Piyush Patel, et al.
  Published: (2016-01-01)
• Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
  by: Ashleigh Shannon, et al.
  Published: (2020-09-01)